Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesiSpecimen Inc

iSpecimen Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.7969 USD -0.05 ( 5.47%)
Last update at 2026-11-05T18:05:00Z
VOLUME
100412
Market Cap
3.35M

Momentum Score

…

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.76
Low
0.85
High
52 Week Price Range
1.32
Low
71.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

iSpecimen operates a digital marketplace that connects researchers and diagnostics firms with providers of human biospecimens and linked clinical data. Long-term growth drivers include rising demand for human samples in precision medicine and diagnostics, expansion of its provider and buyer network, and potential monetization of associated data, which may support scalable revenue.

Material risks include regulatory and privacy compliance, dependence on supply partners or large customers, competitive alternatives among biorepositories and marketplaces, and execution risk in scaling and monetizing the platform.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.84
Dividend Yield
-
Revenue TTM
0.47M
Revenue Per Share
0.90
Gross Profit TTM
-0.50M
Debt / Equity
0.09
ROE
-968.47%
Net Debt
-6.61M
ROCE
-317.49%
Diluted EPS TTM
-45.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.49M -12.50M -11.10M -10.25M -8.96M
Net income -10.49M -12.50M -11.10M -9.04M -10.02M
Selling general administrative 4.30M 7.70M 7.72M 8.93M 6.98M
Selling and marketing expenses 2.30M 4.95M 3.96M 3.45M 2.42M
Gross profit 0.02M 3.99M 5.11M 5.65M 5.89M
Reconciled depreciation 1.73M 2.29M 2.12M 1.21M 1.00M
Ebit -10.48M -12.67M -10.87M -10.19M -5.93M
Ebitda -8.75M -10.38M -8.80M -10.01M -5.96M
Depreciation and amortization 1.73M 2.29M 2.07M 0.18M -0.03M
Operating income -8.98M -12.73M -11.17M -10.19M -5.93M
Other operating expenses 10.91M 22.02M 21.10M 20.59M 17.06M
Interest expense 0.00M 0.22M 0.23M 0.24M 2.10M
Tax provision - - - - 0.00M
Interest income 0.00M 0.04M 0.34M 0.17M 0.01M
Net interest income -0.01M -0.18M 0.11M -0.07M -2.09M
Income tax expense - - 0.00M -1.21M 1.05M
Total revenue 1.93M 9.29M 9.93M 10.40M 11.14M
Total operating expenses 9.00M 16.72M 16.28M 15.83M 11.81M
Cost of revenue 1.90M 5.30M 4.82M 4.76M 5.25M
Total other income expense net -1.51M 0.23M 0.07M -0.06M -3.04M
Net income from continuing ops -10.49M -12.50M -11.10M -10.25M -8.96M
Net income applicable to common shares - - - -10.25M -8.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.53M 9.35M 15.82M 24.62M 35.72M
Intangible assets 1.00M 5.33M 7.23M 4.50M 2.71M
Other current assets 0.03M 0.26M 0.29M 0.30M 3.33M
Total liab 6.44M 6.04M 6.08M 4.31M 5.93M
Total stockholder equity 3.09M 3.31M 9.74M 20.31M 29.79M
Other current liab 0.62M 1.17M 1.54M 1.53M 1.02M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -82.35M -71.86M -59.36M -48.27M -38.02M
Other assets - - 0.00M 0.03M 0.03M
Cash 6.88M 1.88M 2.34M 15.31M 27.74M
Total current liabilities 6.23M 5.77M 6.05M 4.28M 2.51M
Current deferred revenue 0.19M 0.36M 0.42M 0.13M 0.65M
Net debt -6.61M -1.57M -2.15M -15.12M -24.32M
Short term debt 0.06M 0.04M 0.17M 0.16M -
Short long term debt total 0.27M 0.31M 0.20M 0.19M 3.42M
Other stockholder equity 85.44M 75.17M 69.10M 68.57M 67.81M
Property plant equipment - - - 0.41M 0.03M
Total current assets 6.95M 3.59M 8.24M 19.68M 32.95M
Net tangible assets - - - 15.81M 27.08M
Short term investments - 0.00M 2.66M - -
Net receivables 0.05M 1.44M 2.94M 4.07M 4.88M
Long term debt - - - - 3.42M
Inventory 0.00M 0.05M - - -3.00M
Accounts payable 5.36M 4.20M 3.93M 2.46M 0.83M
Accumulated other comprehensive income - - 0.00M - -35.72M
Non currrent assets other 1.28M 0.01M 0.03M 0.03M 0.03M
Non current assets total 2.58M 5.76M 7.58M 4.94M 2.77M
Capital lease obligations 0.27M 0.31M 0.20M 0.19M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 1.98M -7.23M -3.19M -1.04M
Change to liabilities - - - 1.10M -1.14M
Total cashflows from investing activities -1.00M 1.98M -7.23M -3.19M -1.04M
Net borrowings - - 0.00M -3.50M 1.00M
Total cash from financing activities 10.24M 5.82M 0.07M -3.42M 38.75M
Change to operating activities - - - 0.54M -1.42M
Net income -10.49M -12.50M -11.10M -10.25M -8.96M
Change in cash 5.00M -0.47M -12.97M -12.43M 27.04M
Begin period cash flow 1.88M 2.34M 15.31M 27.74M 0.70M
End period cash flow 6.88M 1.88M 2.34M 15.31M 27.74M
Total cash from operating activities -4.24M -8.26M -5.81M -5.82M -10.67M
Issuance of capital stock 11.25M 1.89M 0.00M 0.00M 41.50M
Depreciation 1.66M 2.29M 2.12M 1.21M 1.00M
Other cashflows from investing activities -5.00M -0.68M -4.73M - -
Change to inventory 0.05M 0.00M - - -2.47M
Change to account receivables 1.34M -0.40M 0.82M 1.30M -1.64M
Other cashflows from financing activities 10.24M 3.93M 0.07M 0.07M 0.25M
Change to netincome - - - 0.79M 1.70M
Capital expenditures 0.00M 0.06M 4.74M 3.19M 1.04M
Change in working capital 2.11M -0.50M 2.59M 2.35M -5.28M
Stock based compensation 0.02M 0.25M 0.46M 0.68M 0.62M
Other non cash items 2.45M 2.19M 0.13M 0.19M 0.89M
Free cash flow -4.24M -8.30M -10.55M -9.01M -11.71M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ISPC
iSpecimen Inc		 -0.05
5.47%		 0.80 - - 7.18 2.13 0.18 0.43
TMO
Thermo Fisher Scientific Inc		 -20.88
2.96%		 685.28 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -6.47
2.75%		 228.46 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 26.96 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -
-%		 25.11 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

iSpecimen Inc

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

8 Cabot Road, Woburn, MA, United States, 01801

781 301 6700

https://ispecimen.com

7

Name Title Year Born
Ms. Tracy Wilson Curley CFO, Treasurer & Interim CEO 1962
Dr. Christopher J. Ianelli M.D., Ph.D. Founder & Director 1968
Mr. Benjamin Bielak Chief Information Officer 1970
Ms. Jill Mullan Sec. & Director 1965
Ms. Dawn Michelle VP of Operations NA
Mr. Eric Langlois Sr. VP of Sales & Bus. Devel. NA
Ms. Carly Lejnieks VP of Marketing NA
Ms. Emily Hubbard VP of Site Management & Devel. NA
Mr. David Wages M.D., Ph.D. Chief Medical Officer NA
Ms. Tracy Wilson Curley CEO, CFO, Treasurer & Director 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…